By the end of this week, Moderna Therapeutics is likely to pull off the biggest initial public offering in biotech history, a $500 million fundraise with sweeping implications for the company, its innovative science, and the drug business as a whole.
Before Moderna — and its audacious plan to upend the industry — tests Wall Street’s appetite, here’s a guide to the outstanding questions pegged to biotech’s most scrutinized unicorn.
About the Author Reprints
As expected, Moderna stock falls from its IPO price on the first day of trading. https://news.alphastreet.com/moderna-nasdaq-mrna-stock-raises-over-600-million-through-ipo-to-debut-on-friday/